La cadena de opciones muestra datos clave de las opciones de acciones de MaxCyte a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para MaxCyte..

MaxCyte (NASDAQ:MXCT) Bolsa, Cadena de Opciones

MaxCyte

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

MaxCyte Inc

JMP Securities analyst Devin Ryan maintains Atlanticus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>) with a Market Outperform and raises the price target from $72 to $75.

News

Price Target

Analyst Ratings

ATLC

JMP Securities Maintains Market Outperform on Atlanticus Holdings, Raises Price Target to $75

<a href="https://www.globenewswire.com/Tracker?data=FROT0CrOiZuuZgKDphfrWVIKnXwM_recXoy12vv1IupBdsOSjr_kjaKL8-cvb0uGGjYK-_p313LlS8opn3sQn5R8rocj4JHPozjchWADijY=">Mullen Automotive Inc.</a> (NASDAQ:<a href="https://www.globenewswire.com/Tracker?data=Mcvtr00mnYD81mPtOnUHSIzYJ88bB17OOH2zpTuzh15jlmLQcffsUGWaNsel_I7avX-aOqf1vfFWs6qzRqJyLVgqoid3FJHvoEobF6aPcVpCzhypNQaZnl-A-yrkNbe4"> MULN</a>) ("Mullen" or the "Company"), an emerging electric vehicle ("EV") manufacturer, announces today that in connection with the Company's plan to change its name to Bollinger Innovations, Inc., NASDAQ recently approved a new stock symbol — BINI. The effective date for the change of the Company's name and stock symbol is yet to be determined.
The Company also announces the rebranding of its Oceanside, California, Commercial Vehicle Center to Bollinger Innovations, Inc. This strategic location, based right off of Interstate 5 in the Southern California gateway city of Oceanside, is situated on the northern tip of San Diego County and just outside of the Camp Pendleton military base. Businesses throughout the San Diego region can easily access the Commercial Vehicle Center and explore available inventory, test drive and purchase the Company's commercial EVs.

MULN

Mullen Automotive Announces Plan To Change Its Name To Bollinger Innovations Inc. And NASDAQ Approval For New Stock Symbol, BINI; Effective Date For Name Change And Stock Symbol Yet To Be Determined

Piper Sandler analyst Mark Lear maintains Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) with a Overweight and raises the price target from $14 to $15.

CRGY

Piper Sandler Maintains Overweight on Crescent Energy, Raises Price Target to $15

WIIM

VLCN

Volcon shares are trading higher after the company announced a $500 million private placement and said it plans to use at least 95% of the proceeds to acquire Bitcoin as its primary treasury reserve asset.

Piper Sandler analyst Mark Lear maintains Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) with a Overweight and raises the price target from $54 to $57.

CIVI

Piper Sandler Maintains Overweight on Civitas Resources, Raises Price Target to $57

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Volcon Announces $500M Private Placement, Will Use At Least 95% Of Gross Proceeds To Acquire Bitcoin, Which Will Serve As Primary Treasury Reseve Asset

Piper Sandler analyst Mark Lear maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Overweight and raises the price target from $159 to $164.

CHRD

Piper Sandler Maintains Overweight on Chord Energy, Raises Price Target to $164

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Scott Marks upgraded Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) from Hold to Buy and raised the price target from $66 to $78. Mondelez International shares closed at $67.47 on Wednesday. <a href="https://www.benzinga.com/quote/mdlz/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Rajat Gupta upgraded the rating for Cars.com Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) from Neutral to Overweight and maintained the price target of $14. Cars.com shares closed at $12.33 on Wednesday. <a href="https://www.benzinga.com/quote/cars/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Daniel Clark upgraded Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) from Market Perform to Outperform and announced a price target of $18. Elanco Animal Health shares closed at $14.51 on Wednesday. <a href="https://www.benzinga.com/quote/elan/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Steven Madden upgraded Steven Madden, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) from Neutral to Buy and boosted the price target from $26 to $32. Steven Madden shares closed at $24.58 on Wednesday. <a href="https://www.benzinga.com/quote/shoo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Zachary Silverberg upgraded the rating for Monarch Casino &amp; Resort, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) from Underweight to Equal-Weight and raised the price target from $83 to $89. Monarch Casino &amp; Resort shares closed at $87.36 on Wednesday. <a href="https://www.benzinga.com/quote/mcri/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MDLZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="621" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17085404/image-221-1024x621.png" alt="" class="wp-image-989724" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17085404/image-221-1024x621.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17085404/image-221-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17085404/image-221-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17085404/image-221.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46439944/jim-cramer-takes-a-pass-on-this-money-losing-utilities-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46439944/jim-cramer-takes-a-pass-on-this-money-losing-utilities-stock">Jim Cramer &#8216;Takes A Pass&#8217; On This Money-Losing Utilities Stock</a></li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Trading Ideas

CARS

ELAN

MCRI

MDLZ

SHOO

This Mondelez International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Piper Sandler analyst Mark Lear maintains Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) with a Neutral and lowers the price target from $5 to $4.

Piper Sandler Maintains Neutral on Berry Corp, Lowers Price Target to $4

The Russell 2000 Index, a benchmark for 2,000 small-cap U.S. stocks, has shown no growth, posting a stagnant -0.57% year-over-year return as of mid-2025. 
What Happened: According to a chart shared by Kevin Gordon, senior investment strategist at Charles Schwab &amp; Co., Inc., "Russell 2000 has made no progress on a y/y basis," highlighting a stark contrast with the S&amp;P 500 index's 12.09% gain over the same period.
The lackluster performance has sparked concerns about the health of small-cap stocks amid a broader market divergence. This comes amid the annual Russell Reconstitution, completed on June 27, which reshuffled the Russell indices.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Russell 2000 has made no progress on a y/y basis <a href="https://t.co/BWerhR5SPX">pic.twitter.com/BWerhR5SPX</a>
&mdash; Kevin Gordon (@KevRGordon) <a href="https://twitter.com/KevRGordon/status/1945811217639231965?ref_src=twsrc%5Etfw">July 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Jeff Buchbinder, the chief equity strategist at LPL Financial, noted in a recent analysis, "While small caps remain significantly smaller than the $56 trillion large cap market, the Russell 2000 still stands as a major global equity market — larger than the entire equity markets of France, Germany, Canada, and Australia.&#8221;
&#8220;In fact, if treated as a standalone market, the Russell 2000 would rank as the sixth largest in the world, trailing only the U.S. Russell 1000, China, Japan, the United Kingdom, and India,&#8221; he added.
Despite its enormity and significance as highlighted by Buchbinder, the small-cap index has underperformed over the past year. Only the top U.S. companies in the S&amp;P 500, weighted by their market capitalization, have been driving the overall gains.
Buchbinder also highlights that the reconstitution saw a record 2.5 billion shares traded in 0.9 seconds, reflecting $102.4 billion in value, yet small-caps failed to capitalize.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46463595/dan-ives-picks-5-stocks-for-2nd-half-of-2025-nvidia-palantir-microsoft-and-more-golden-age-of-tech-is-here-with-ai-revolution">Dan Ives Picks 5 Stocks For 2nd Half Of 2025: Nvidia, Palantir, Microsoft And More: &#8216;Golden Age Of Tech Is Here With AI Revolution&#8217;</a>
Why It Matters: Meanwhile, the Russell 1000, comprising the largest 1,000 stocks, is thriving, with its top 10 constituents now accounting for $18 trillion of the $55.7 trillion index. This index has returned 12.47% over the past year.
Buchbinder explained that &#8220;turnover within indexes remained relatively muted,&#8221; despite the reconstitution because the &#8220;uptick in volatility on reconstitution day has come down in recent years.&#8221;
This happens as FTSE Russell releases preliminary changes nearly two months in advance, allowing institutional investors and traders the ability to adjust their portfolios ahead of time.
"For investors considering adjustments to their portfolios following these changes, we suggest staying patient while keeping in mind that volatility may pick up over the next few weeks around tariff headlines, incoming inflation data, the upcoming earnings season, and historical seasonal weakness," advised Buchbinder.
Price Action: The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the Russell 2000, S&amp;P 500, and Nasdaq 100 indices, respectively, were mixed in premarket on Thursday.
The IWM was down 0.27% to $220.43, SPY was up 0.03% at $624.41, while the QQQ advanced 0.17% to $558.23, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46461053/federal-reserves-beige-book-reveals-tariff-driven-profit-squeeze-as-businesses-avoid-price-hikes-what-it-means-for-consumers" target="_blank" rel="noreferrer noopener">Federal Reserve's Beige Book Reveals Tariff-Driven Profit Squeeze As Businesses Avoid Price Hikes — What It Means for Consumers</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: khunkornStudio via Shutterstock

Equities

Russell 2000 Makes 'No Progress' Amid Reconstitution Shake-Up: Are Small-Caps Struggling As Large-Caps Soar?

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $9 price target.

GOVX

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $9 Price Target

Piper Sandler analyst Mark Lear maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and raises the price target from $19 to $21.

Piper Sandler Maintains Neutral on APA, Raises Price Target to $21

BCAB

BioAtla To Present First-In-Human Phase I Study Of Dual- CAB EpCAM x CD3 Bispecific T-Cell Engager, BA3182, In Patients With Treatment Refractory Metastatic Adenocarcinoma, At ESMO TAT Asia Meeting

D. Boral Capital analyst Jason Kolbert initiates coverage on Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) with a Buy rating and announces Price Target of $11.

Initiation

XAIR

D. Boral Capital Initiates Coverage On Beyond Air with Buy Rating, Announces Price Target of $11

BRCC

BRC shares are trading lower after the company announced it has priced a $35 million public offering of common stock.

ACTU

Actuate Therapeutics Initiates Planning Of Phase 2 Trial Of Elraglusib In Children, Adolescents, And Adults With Refractory/Resistant Ewing Sarcoma

HYPR

Hyperfine shares are trading higher after the company announced the first commercial sales of its Swoop system, powered by Optive AI software.

Actuate Therapeutics Announces End Of Phase 1 Portion Of Clinical Study Evaluating Elraglusib Monotherapy Or In Combination With Irinotecan, Irinotecan Plus Temozolomide, Or With Cyclophosphamide Plus Topotecan In Pediatric Patients With Refractory Malignancies

Offerings

NioCorp Prices $45.0M Public Offering Of 13,850,000 Shares At $3.25/Share

Guidance

IQST

IQSTEL Jun. Revenue $27.3M, Up From $23.7M In May; Reports Prelim. 1H Revenue Of $128.8M

Press Releases

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Health Care

Contracts

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Earnings

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

Comments

MaxCyte

MaxCyte (MXCT) Opciones

MaxCyte (NASDAQ:MXCT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL